Gamco Investors INC. ET AL cut its position in shares of Alere Inc (NYSE:ALR) by 10.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 454,922 shares of the medical research company’s stock after selling 55,030 shares during the quarter. Gamco Investors INC. ET AL owned 0.52% of Alere worth $23,196,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board grew its position in Alere by 238.6% during the third quarter. State of Wisconsin Investment Board now owns 613,409 shares of the medical research company’s stock worth $31,278,000 after buying an additional 432,268 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Alere during the third quarter worth about $4,110,000. Athos Capital Ltd grew its position in Alere by 90.1% during the third quarter. Athos Capital Ltd now owns 114,040 shares of the medical research company’s stock worth $7,554,000 after buying an additional 54,040 shares in the last quarter. Havens Advisors LLC grew its position in Alere by 85.7% during the third quarter. Havens Advisors LLC now owns 260,000 shares of the medical research company’s stock worth $13,257,000 after buying an additional 120,000 shares in the last quarter. Finally, Banco BTG Pactual S.A. acquired a new stake in Alere during the second quarter worth about $4,999,000. 89.33% of the stock is currently owned by institutional investors and hedge funds.

Shares of Alere Inc (NYSE:ALR) opened at $50.99 on Thursday. Alere Inc has a 1-year low of $34.41 and a 1-year high of $51.00. The company has a debt-to-equity ratio of 2.43, a current ratio of 2.04 and a quick ratio of 1.54.

A number of equities research analysts recently weighed in on ALR shares. BidaskClub downgraded Alere from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Zacks Investment Research downgraded Alere from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Finally, Canaccord Genuity reissued a “hold” rating and set a $51.00 target price on shares of Alere in a research report on Tuesday, September 19th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $51.00.

ILLEGAL ACTIVITY WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/09/alere-inc-alr-shares-sold-by-gamco-investors-inc-et-al.html.

About Alere

Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.

Institutional Ownership by Quarter for Alere (NYSE:ALR)

Receive News & Stock Ratings for Alere Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc and related stocks with our FREE daily email newsletter.